Jeong Hyun-ae

Article Free Access Share on Lower bounds and efficient algorithms for multiprocessor scheduling of dags with communication delays Authors: H. Jung Mathematics Dept., Humboldt Univ., GDR Mathematics Dept., Humboldt Univ., GDRView Profile , L. Kirousis Computer Technology Institute, Patras Univ., Greece Computer Technology Institute, Patras Univ., GreeceView Profile , P. Spirakis Computer Technology Institute, Patras Univ., Greece and Courant Inst. Math. Sciences, NYU Computer Technology Institut

BACKGROUND: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. METHODS: A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. RESULTS:

Importance: Over the past 10 years, treatment of non-small cell lung cancer (NSCLC) has been continually revolutionized. However, standard clinical trials may not reflect current multiple lines of treatment and corresponding outcomes in a timely manner. Objective: To investigate outcomes associated with new treatment of NSCLC in a clinical setting. Design, Setting, and Participants: This cohort study included patients with NSCLC between January 1, 2010, and November 30, 2020, who received any an

PURPOSE: Although programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors are promising agents for recurrent or metastatic nasopharyngeal carcinoma (NPC), PD-1/PD-L1 inhibitor monotherapy has shown modest efficacy. This study evaluated the efficacy and safety of nivolumab plus gemcitabine in patients with NPC who failed prior platinum-based chemotherapy. PATIENTS AND METHODS: This is a phase II, multicenter, open-label, single-arm study. Patients with recurrent or metastatic NPC rec

BACKGROUND: Urachal cancer is a rare malignancy that accounts for <1% of bladder cancers. There is currently no consensus on the diagnosis and management of urachal cancer and there are very few reports on palliative chemotherapy for unresectable disease. We delineate the clinical features and treatment outcome of urachal cancer, in particular the relevance of palliative chemotherapy in recurrent, metastatic disease. METHODS: The clinicopathologic variables and treatment outcome of patients who

Through there are some limitation as a retrospective study, afatinib showed similar CNS response rates, superior CNS-PFS and cumulative incidence of CNS failure, compared with gefitinib or erlotinib.

Sequential afatinib and osimertinib demonstrated encouraging activity in patients with EGFR mutation-positive NSCLC and acquired T790M. Activity was observed across all subgroups, including patients with poor ECOG PS or brain metastases. ECOG PS and incidence of brain metastases remained stable prior to, and after, afatinib treatment.

Optical gain spectra of GaInAsP/InP double heterostructures (DHs) have been recorded in the temperature range of 80–300 K. These data are compared with threshold currents of DHs injection lasers fabricated from the same wafers. An identical behavior of maximum optical gain and threshold current is observed, i.e., two T0 values (100 and 63 K) with a break-point temperature of TB ≃260 K are found. Furthermore, characteristic changes of the optical gain spectrum are observed close to the break-poin

PURPOSE: In early-stage, EGFR mutation-positive (EGFR-M+) non-small cell lung cancer (NSCLC), surgery remains the primary treatment, without personalized adjuvant treatments. We aimed to identify risk factors for recurrence-free survival (RFS) to suggest personalized adjuvant strategies in resected early-stage EGFR-M+ NSCLC. EXPERIMENTAL DESIGN: From January 2008 to August 2020, a total of 2,340 patients with pathologic stage (pStage) IB-IIIA, non-squamous NSCLC underwent curative surgery. To id

Macrocytosis developed with more frequent and prolonged use of capecitabine. It is possible that association with treatment outcomes warrants further investigation.